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When I was an undergraduate working at the National Research
Laboratories in Ottawa, I asked the local Nobelist, Gerhart
Herzberg (Nobel Prize for Chemistry, 1972), if he could rec-
ommend a good book on the Manhattan Project. He did not
work directly on the atomic bomb, but he knew many of the
key scientists in their postwar careers. He couldn’t recommend
a specific book, but he told me to read many books on the same
topic. He said the history of science was fraught with error, since
it was usually not recorded until a Nobel Prize was awarded.
By then, it was too late to get it right.
In his book Cracking the Genome, Kevin Davies doesn’t wait
that long and tells a version of biology’s superproject just as the
“draft” sequence of the human genome is being announced.
Davies, well known to the American Society of Human Genetics
as a founding editor of Nature Genetics, is qualified to write a
behind-the-scenes account of the Human Genome Project
(HGP). The book is not intended to be the definitive record of
the HGP but aims to capture the excitement and majesty of the
quest to crack the genetic code.
The story primarily focuses on HGP events of the last 3 years,
from the initiation of the DNA-sequencing phase of the publicly
funded effort, to the entry of Celera Genomics into the race.
There is little discussion of the important scientific events pre-
ceding the sequencing stage. The obvious main characters, Fran-
cis Collins and Craig Venter, are portrayed as modern-day
knights of good and not-so-good, respectively, tangled in a quest
for biology’s Holy Grail.
As in any good novel, character development is crucial. Venter
is portrayed as the hypercompetitive scientist that he seems to
be. Through his large-scale expressed-sequence tag sequencing,
establishment of The Institute for Genomic Research, and se-
quencing of bacterial and Drosophila genomes, his actions be-
come predictable. To know Venter, one only has to know Cel-
era’s corporate motto “Discovery can’t wait.” The development
of Collins’s character, however, does not give enough gritty detail
to foreshadow how he might deal with Celera’s direct assault
on the HGP. Self-billed as the “field marshal” of “Team Se-
quence,” Collins and the other HGP sequence leaders are es-
sentially thrown into a boxing ring wearing a blindfold. Celera
can see the public sequencing consortium’s strengths and weak-
nesses—and, most importantly, their data—but the public HGP
is ignorant of Celera’s actions. In his earlier, highly touted suc-
cesses in cloning disease genes, Collins often was only a collab-
orator on larger projects. How could he (or any academic, for
that matter) stand up and deal with aggressive competition from
what was soon to become a billion-dollar corporation?
Davies does not answer the nagging question of whether the
decision to complete a “draft” sequence of the human genome
was a pre-Celera action to get the public HGP moving or a
reaction to Venter throwing his gloves into the ring. Nor does
he delve into any details of what the initial level of support was
from the non-USA sequencing consortia members for such a
major deviation in sequencing strategy. They had almost com-
pleted the “finished” sequence of chromosomes 21 and 22. Con-
tinuation of a perhaps less altruistic approach of chromosome-
by-chromosome sequencing (even in a draft form) may have
limited Celera’s ability to claim victory over the genome, without
having to invest a lot more time and resources. We can hear
some frustration in Maynard Olson’s comment inNature’s “Ge-
nome” issue: “each new round of press conferences announcing
the human genome has been sequenced saps the morale of those
who must come to work each day to do what they read in the
newspapers has already been done” (Nature 409:816–818). Ul-
timately, the completeness and accuracy of the different versions
of the human genome sequence will be tested over the next
decade by many types of experimentation. However, for this
book, more investigation into the politics behind these deci-
sions would have moved it from being a good read to an ex-
cellent one.
This work has one important strength. It is effective in show-
ing that each success of the HGP, from conceptualization
through to mapping and DNA sequencing, followed close be-
hind advances in technology and implementation of new strat-
egies, one building on the other. This large-scale, technology-
driven approach epitomizes how science will continue to be
conducted into the 21st century.
Many of us who are working in the field of genetics and on
the HGP may be too close to the topic to fully appreciate such
an exhilarating story. Can you imagine the headlines in 1944,
if a private corporation exploded a bomb that was created using
many of the secrets of the Manhattan effort? What if an upstart
aerospace company claimed to have the first moon rock in their
hands, as Apollo was orbiting? It’s just a great story, and, if
only for this reason, Cracking the Genome should be read. It
should also serve as a precursor for more books describing dif-
ferent versions of HGP events. Our community should read these
books and, whenever possible, assist the authors in writing them.
This will be the best way to ensure that the facts are accurate,
so, when our students come to ask us about the history of the
HGP, we can point them to the best sources.
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